Xavier Mariette

Research interests

Publications

• Multi-ancestry genome-wide association analyses identify novel genetic mechanisms in rheumatoid arthritis

  Nature Genetics · 2022 · https://doi.org/10.1038/s41588-022-01213-w

• Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial

  The Lancet Respiratory Medicine · 2021 · https://doi.org/10.1016/s2213-2600(20)30556-7

• Systemic and organ-specific immune-related manifestations of COVID-19

  Nature Reviews Rheumatology · 2021 · 10.1038/s41584-021-00608-z

• Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia

  JAMA Internal Medicine · 2020 · https://doi.org/10.1001/jamainternmed.2020.6820

• Immune-related adverse events of checkpoint inhibitors

  Nature Reviews Disease Primers · 2020 · 10.1038/s41572-020-0160-6

• EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update

  Annals of the Rheumatic Diseases · 2020 · https://doi.org/10.1136/annrheumdis-2019-216655

• EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies

  Annals of the Rheumatic Diseases · 2019 · 10.1136/annrheumdis-2019-216114

• 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus

  Annals of the Rheumatic Diseases · 2019 · https://doi.org/10.1136/annrheumdis-2018-214819

• 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus

  Arthritis & Rheumatology · 2019 · https://doi.org/10.1002/art.40930

• B cells in the pathogenesis of primary Sjögren syndrome

  Nature Reviews Rheumatology · 2018 · 10.1038/nrrheum.2018.1

• Primary Sjögren’s Syndrome

  New England Journal of Medicine · 2018 · 10.1056/nejmcp1702514

• Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study

  Annals of the Rheumatic Diseases · 2017 · 10.1136/annrheumdis-2017-212196

• Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials

  Annals of the Rheumatic Diseases · 2017 · 10.1136/annrheumdis-2016-210457

• Standardisation of labial salivary gland histopathology in clinical trials in primary Sjögren's syndrome

  Annals of the Rheumatic Diseases · 2016 · https://doi.org/10.1136/annrheumdis-2016-210448

• A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)

  Annals of the Rheumatic Diseases · 2016 · https://doi.org/10.1136/annrheumdis-2016-209519

• Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force

  Annals of the Rheumatic Diseases · 2016 · 10.1136/annrheumdis-2015-208916

• Sjögren syndrome

  Nature Reviews Disease Primers · 2016 · https://doi.org/10.1038/nrdp.2016.47

• Non–TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug

  JAMA · 2016 · https://doi.org/10.1001/jama.2016.13512

• EULAR Sjögren's syndrome disease activity index (ESSDAI): a user guide

  RMD Open · 2015 · https://doi.org/10.1136/rmdopen-2014-000022

• Characterization of systemic disease in primary Sjögren's syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements

  Lara D. Veeken · 2015 · 10.1093/rheumatology/kev200

• Treat-to-target in systemic lupus erythematosus: recommendations from an international task force

  Annals of the Rheumatic Diseases · 2014 · https://doi.org/10.1136/annrheumdis-2013-205139

• FRI0298 The Impact of DMARD Co-Therapy on Abatacept Effectiveness in Rheumatoid Arthritis Patients. A Pan-European Analysis of RA Registries

  Annals of the Rheumatic Diseases · 2014 · https://doi.org/10.1136/annrheumdis-2014-eular.3004

• Validation of EULAR primary Sjögren’s syndrome disease activity (ESSDAI) and patient indexes (ESSPRI)

  Annals of the Rheumatic Diseases · 2014 · https://doi.org/10.1136/annrheumdis-2013-204615

• Treatment of Primary Sjögren Syndrome With Rituximab

  Annals of Internal Medicine · 2014 · https://doi.org/10.7326/m13-1085

• Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI)

  Annals of the Rheumatic Diseases · 2014 · https://doi.org/10.1136/annrheumdis-2014-206008

• Effects of Hydroxychloroquine on Symptomatic Improvement in Primary Sjögren Syndrome

  JAMA · 2014 · https://doi.org/10.1001/jama.2014.7682

• Sjögren Syndrome‐associated lymphomas: an update on pathogenesis and management

  British Journal of Haematology · 2014 · 10.1111/bjh.13192

• Genetics of rheumatoid arthritis contributes to biology and drug discovery

  Nature · 2013 · https://doi.org/10.1038/nature12873

• EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

  Annals of the Rheumatic Diseases · 2013 · https://doi.org/10.1136/annrheumdis-2013-204573

• Advances in understanding the pathogenesis of primary Sjögren's syndrome

  Nature Reviews Rheumatology · 2013 · 10.1038/nrrheum.2013.110

• Efficacy and safety of belimumab in primary Sjögren’s syndrome: results of the BELISS open-label phase II study

  Annals of the Rheumatic Diseases · 2013 · 10.1136/annrheumdis-2013-203991

• Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjögren's syndrome

  Nature Genetics · 2013 · 10.1038/ng.2792

• Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective

  Annals of the Rheumatic Diseases · 2012 · 10.1136/annrheumdis-2012-202545

• Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study)

  Annals of the Rheumatic Diseases · 2012 · https://doi.org/10.1136/annrheumdis-2012-202322

• Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis

  Annals of the Rheumatic Diseases · 2011 · https://doi.org/10.1136/ard.2010.149419

• EULAR Sjögren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren's syndrome

  Annals of the Rheumatic Diseases · 2009 · https://doi.org/10.1136/ard.2009.110619

• Randomized Phase II Trial of Denosumab in Patients With Bone Metastases From Prostate Cancer, Breast Cancer, or Other Neoplasms After Intravenous Bisphosphonates

  Journal of Clinical Oncology · 2009 · 10.1200/jco.2008.19.2146

• B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjögren's syndrome

  Arthritis Research & Therapy · 2006 · 10.1186/ar1912

• A Phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases

  Cancer · 2003 · 10.1002/cncr.11138

• The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome

  Annals of the Rheumatic Diseases · 2003 · 10.1136/ard.62.2.168

• Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France

  Blood · 2002 · 10.1182/blood.v99.11.3909

Current projects

No projects listed.